A detailed history of Sfe Investment Counsel transactions in Eli Lilly & CO stock. As of the latest transaction made, Sfe Investment Counsel holds 450 shares of LLY stock, worth $339,750. This represents 0.09% of its overall portfolio holdings.

Number of Shares
450
Previous 510 11.76%
Holding current value
$339,750
Previous $461,000 13.67%
% of portfolio
0.09%
Previous 0.11%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$772.14 - $960.02 $46,328 - $57,601
-60 Reduced 11.76%
450 $398,000
Q4 2023

Jan 31, 2024

SELL
$525.19 - $619.13 $5,251 - $6,191
-10 Reduced 1.92%
510 $297,000
Q3 2023

Oct 24, 2023

SELL
$434.7 - $599.3 $4,347 - $5,993
-10 Reduced 1.89%
520 $279,000
Q2 2023

Jul 24, 2023

BUY
$350.74 - $468.98 $10,522 - $14,069
30 Added 6.0%
530 $248,000
Q1 2023

May 08, 2023

BUY
$310.63 - $364.82 $155,315 - $182,410
500 New
500 $171,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $717B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Sfe Investment Counsel Portfolio

Follow Sfe Investment Counsel and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sfe Investment Counsel, based on Form 13F filings with the SEC.

News

Stay updated on Sfe Investment Counsel with notifications on news.